$3.79
-0.20 (-5.01%)
Open$3.98
Previous Close$3.99
Day High$4.00
Day Low$3.58
52W High$4.90
52W Low$1.70
Volume—
Avg Volume273.3K
Market Cap62.76M
P/E Ratio—
EPS$-4.40
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+454.1% upside
Current
$3.79
$3.79
Target
$21.00
$21.00
$13.91
$21.00 avg
$28.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.03M | 5.08M | 4.69M |
| Net Income | 1.10M | 914.1K | 814.2K |
| Profit Margin | 21.9% | 18.0% | 17.4% |
| EBITDA | 1.45M | 1.42M | 1.49M |
| Free Cash Flow | 1.19M | 761.6K | 738.1K |
| Rev Growth | -9.3% | +7.5% | +3.9% |
| Debt/Equity | 1.05 | 1.23 | 1.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |